Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz gmbh - folinska kislina - raztopina za injiciranje/infundiranje - folinska kislina 10 mg / 1 ml - kalcijev folinat

Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatične neoplazme - terapevtski radiofarmacevtiki - xofigo je indicirano za zdravljenje odraslih s kastracijo-ki se upira raka prostate, simptomatsko kosti metastaz in ni znano visceralno metastaz.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strides arcolab international limited - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi deutschland gmbh - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strides arcolab international limited - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi deutschland gmbh - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - latanoprost; timolol - kapljice za oko, raztopina - latanoprost 0,05 mg / 1 ml  timolol5 mg / 1 ml; timolol 5 mg / 1 ml - timolol, kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

wÖrwag pharma - venlafaksin - kapsula s podaljšanim sproščanjem, trda - venlafaksin 37,5 mg / 1 kapsula - venlafaksin

Evropska unija - slovenščina - EMA (European Medicines Agency)

astellas pharma gmbh - takrolimus - dermatitis, atopic - drugi dermatološki preparati - zdravljenje zmernega do hudega atopičnega dermatitisa pri odraslih, ki se ne odzivajo ali ne prenašajo na konvencionalne terapije, kot so lokalni kortikosteroidi. zdravljenje zmernega do hudega atopičnega dermatitisa pri otrocih (starih 2 leti in več), ki se ni ustrezno odzvalo na običajne terapije, kot so lokalni kortikosteroidi. vzdrževanje zdravljenje zmerno do hudo atopijskega dermatitisa za preprečevanje rakete in podaljšanje flare-prosto časovnih presledkih v pri bolnikih z visoko frekvenco bolezni exacerbations (i. prisotnih 4 ali več-krat na leto), ki so imeli prvi odziv na največ 6 tednov zdravljenja dvakrat dnevno takrolimus mazila (lezije očiščeno, skoraj očiščeno ali rahlo vpliva).

Evropska unija - slovenščina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.